EUVIMEDEUVIMED entdecken
MetaanalyseOpen Access · CC BY-NC 4.0

Safety of Empagliflozin: An Individual Participant-Level Data Meta-Analysis from Four Large Trials

Christoph Wanner iD, Hristo Iliev, Nathalia Duarte, Elke Schueler iD, Ana Rita Soares, Vikram Thanam, Egon Pfarr iD

Advances in Therapy · 2024-07 · 41 (7) · 2826-2844

DOI: 10.1007/s12325-024-02879-w ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Advances in Therapy, online erschienen am 21.05.2024. Verfasst von Christoph Wanner und 6 weiteren Autor:innen. Beteiligte Einrichtung: University Hospital Würzburg, Würzburg, Germany. Wanner_C@ukw.de. Hauptthemen laut MEDLINE: Glucosides, Benzhydryl Compounds, Diabetes Mellitus, Type 2, Sodium-Glucose Transporter 2 Inhibitors. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Empagliflozin is a sodium-glucose co-transporter-2 inhibitor used to treat type 2 diabetes (T2D) to improve glycemic control, reduce risk of cardiovascular death in patients with T2D, and treat patients with symptomatic chronic heart failure (HF) and chronic kidney disease (CKD). The safety profile of empagliflozin is well documented, although adverse events (AEs) remain of interest to clinicians. This study provides an up-to-date safety evaluation of empagliflozin. METHODS: Data were pooled from four long-term trials which included: patients with T2D and established cardiovascular disease (EMPA-REG OUTCOME), patients with HF, with/without diabetes (EMPEROR-Reduced and EMPEROR-Preserved), and patients with CKD, with/without diabetes (EMPA-KIDNEY). Since three of the four trials evaluated empagliflozin 10 mg, the meta-analysis was restricted to this dose. RESULTS: Total trial medication exposure was 19,727 patient-years for patients who received empagliflozin (n = 10,472) and 19,447 patient-years for placebo (n = 10,461). The percentages of patients with serious AEs, fatal AEs, and AEs leading to discontinuation were similar for both groups. The incidences of serious urinary tract infection and serious pyelonephritis or urosepsis were similar for both groups but higher for women taking empagliflozin versus placebo. Serious genital infections were not increased with empagliflozin versus placebo. There was a slight increase in ketoacidosis and serious volume depletion in patients who received empagliflozin versus placebo. The occurrence of serious acute kidney injury was lower with empagliflozin versus placebo. Empagliflozin was not associated with an increased incidence of severe hypoglycemia, bone fractures, or lower limb amputations. Empagliflozin is therefore considered safe in people without diabetes, the elderly, patients with very low estimated glomerular filtration rate, low body mass index, and HF. Safety is unaltered by blood pressure, concomitant medication for hypertension, HF, and immunosuppression. CONCLUSION: This meta-analysis of long-term safety data extends current knowledge and confirms the safety and tolerability of empagliflozin. Empagliflozin is used in adults with type 2 diabetes mellitus (T2D) to improve blood glucose control and in people with T2D and established cardiovascular disease to reduce the risk of death from cardiovascular disease. Also, it is used to treat people with chronic heart failure or chronic kidney disease. Although many clinical trials have shown the effectiveness and safety of empagliflozin, the evaluation of adverse events (AEs) remains of interest. This study further examined the safety of empagliflozin by analyzing four large, long-term clinical trials. These trials included over 20,900 patients with T2D and established cardiovascular disease, patients with heart failure, and patients with chronic kidney disease. Adverse events of interest were pooled and analyzed. Results show the risk of the investigated AEs was similar whether patients had received empagliflozin or placebo. The risk of urinary tract infections, including those that spread to the kidneys, was higher for women taking empagliflozin versus placebo. Ketoacidosis was rare but more frequent in patients taking empagliflozin. A reduction in blood volume was slightly more frequent in people taking empagliflozin versus placebo. The risk of kidney injury was reduced in patients taking empagliflozin versus placebo. The risk of genital infections, hypoglycemia, bone fractures, or lower limb amputations was not increased with empagliflozin. No new safety concerns were raised, including in people who were elderly, had kidney disease, low body weight, T2D, or heart failure. This analysis is consistent with current knowledge of empagliflozin safety in a broad range of patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlucosidesBenzhydryl CompoundsDiabetes Mellitus, Type 2Sodium-Glucose Transporter 2 InhibitorsCardiovascular DiseasesHumansFemaleMaleRenal Insufficiency, ChronicHeart FailureMiddle AgedAgedHypoglycemic AgentsRandomized Controlled Trials as Topic

Stichwörter der Autor:innen

Adverse drug eventAdverse drug reactionDrug safetyEmpagliflozinSGLT2 inhibitors

Substanzen

empagliflozinGlucosidesBenzhydryl CompoundsSodium-Glucose Transporter 2 InhibitorsHypoglycemic Agents

Autor:innen und Institutionen

  • University Hospital Würzburg, Würzburg, Germany. Wanner_C@ukw.de.
  • Boehringer Ingelheim International GmbH, Ingelheim, Germany.
  • Mainanalytics GmbH, Sulzbach, Germany.
  • Eli Lilly and Company, Lisbon, Portugal.

ORCID-Profile: Christoph Wanner, Elke Schueler, Egon Pfarr

Zitieren

APA

Wanner, C., Iliev, H., Duarte, N., Schueler, E., Soares, A. R., Thanam, V., & Pfarr, E. (2024). Safety of Empagliflozin: An Individual Participant-Level Data Meta-Analysis from Four Large Trials. Advances in Therapy, 41(7), 2826-2844. https://doi.org/10.1007/s12325-024-02879-w

Vancouver

Wanner C, Iliev H, Duarte N, Schueler E, Soares AR, Thanam V, et al. Safety of Empagliflozin: An Individual Participant-Level Data Meta-Analysis from Four Large Trials. Advances in Therapy. 2024;41(7):2826-2844. doi:10.1007/s12325-024-02879-w

BibTeX
@article{Wanner2024,
  author = {Wanner, Christoph and Iliev, Hristo and Duarte, Nathalia and Schueler, Elke and Soares, Ana Rita and Thanam, Vikram and Pfarr, Egon},
  title = {Safety of Empagliflozin: An Individual Participant-Level Data Meta-Analysis from Four Large Trials},
  journal = {Advances in Therapy},
  year = {2024},
  volume = {41},
  number = {7},
  pages = {2826--2844},
  doi = {10.1007/s12325-024-02879-w}
}
Kostenlos starten →